Gebbia V, Galetta D, Majello E, Valenza R, Colucci G, Gebbia N
Service of Chemotherapy, Policlinico, University of Palermo, Italy.
Am J Clin Oncol. 1996 Jun;19(3):278-80. doi: 10.1097/00000421-199606000-00014.
Thirty-five patients affected by stage III-IV non-small-cell lung carcinomas were treated with ifosfamide 3 gr/m2 plus MESNA as uroprotector on day 1 and vinorelbine 25 mg/m2 i.v. bolus on day 1 and 8. This cycle was repeated every 21 days. Over a total of 35 evaluable patients, the overall response rate was 34% (95% CL 18-54%). One patient experienced a complete response with a duration of 7.2+ months, and 11 patients a partial response with a mean duration of 5.9+ months. Seven patients had no change and 16 improved. The overall survival was 7.6+ months. Over a total of 145 cycles, the most frequent toxicity was myelosuppression, but grade 3 leukopenia and grade 2 thrombocytopenia were seen only in 14% and 9% of cases, respectively. Only one patient suffered grade 4 leukopenia. Gastrointestinal toxicity was minimal; only five patients (14%) complained of grade 3 vomiting. This combination regimen can be safely given on an outpatient regimen, but it is relatively active in advanced non-small-cell lung cancer. However, it should be noted that >50% of the patients in this series had a performance status of <80 and >50% were older than 65 years.
35例Ⅲ-Ⅳ期非小细胞肺癌患者接受如下治疗：第1天给予异环磷酰胺3 g/m²加美司钠作为尿路保护剂，第1天和第8天静脉推注长春瑞滨25 mg/m²。每21天重复此周期。在总共35例可评估患者中，总缓解率为34%（95%可信区间18-54%）。1例患者完全缓解，持续时间为7.2+个月，11例患者部分缓解，平均持续时间为5.9+个月。7例患者病情无变化，16例患者病情改善。总生存期为7.6+个月。在总共145个周期中，最常见的毒性是骨髓抑制，但3级白细胞减少和2级血小板减少分别仅见于14%和9%的病例。仅1例患者出现4级白细胞减少。胃肠道毒性最小；仅5例患者（14%）主诉3级呕吐。这种联合方案可以在门诊方案中安全给药，但在晚期非小细胞肺癌中相对有效。然而，应该注意的是，该系列中>50%的患者体能状态<80，>50%的患者年龄超过65岁。
